Core Insights - The healthcare sector requires companies to develop unique technologies or products to maintain long-term success and withstand competition [1] - Identified companies with potential for sustained success include argenx SE, ICON plc, and Edwards Lifesciences Corp [2] Company Summaries Argenx SE - Argenx specializes in treatments for autoimmune diseases, particularly with its FDA-approved drug efgartigimod (VYVGART), which targets chronic autoimmune conditions like myasthenia gravis [2][3] - The company reported a 97% year-over-year increase in product sales, indicating strong market demand and growth potential [4] - All 21 analysts covering argenx have assigned a Buy rating, reflecting confidence in its future performance [4] ICON plc - ICON is a leading contract research organization (CRO) that provides outsourced development and commercialization services, particularly excelling in decentralized clinical trials [6][7] - Following its $12 billion acquisition of PRA Health Sciences, ICON has solidified its position as one of the largest CROs globally [6] - The company has demonstrated revenue resilience, with a commitment to shareholder value through $250 million in share repurchases and an authorization for up to $1 billion in additional buybacks [8] Edwards Lifesciences Corp - Edwards Lifesciences is a leader in medical devices for structural heart disease, particularly known for its transcatheter aortic valve replacement (TAVR) system [9][10] - The company has a strong market share in TAVR, with a favorable shift towards this minimally invasive procedure among surgeons [10] - Despite a slight decline in earnings per share year-over-year, analysts project over 12% earnings growth for the upcoming year, supported by robust R&D investments [11][12]